专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018091447A1 CANCER TREATMENT BY GLYCEROL-3-PHOSPHATE DEHYDROGENASE 1 INHIBITION 审中-公开
公开(公告)号：WO2018091447A1
公开(公告)日：2018-05-24
申请号：PCT/EP2017/079158
申请日：2017-11-14
申请人： BAYER PHARMA AKTIENGESELLSCHAFT , DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ)
发明人： RUSU, Patricia , HAI-KUN, Liu
IPC分类号： C12N15/113 , A61K31/7068
摘要： The present invention relates to an inhibitor of glycerol-3-phosphate dehydrogenase 1 (GPD1 inhibitor) for use in treatment and/or prevention of cancer. The present invention further relates to a kit comprising a GPD1 inhibitor comprised in a housing; to a method for identifying a subject suffering from cancer susceptible to cancer treatment by administration of a GPD1 inhibitor comprising a) determining in a sample of said subject the amount of a GPD1 gene product, b) comparing said amount determined in step a) to a reference, and c) based on the result of step b), identifying a subject susceptible to cancer treatment by administration of a GPD1 inhibitor; and to further means and methods related thereto.

2. 发明申请

WO2018188785A1 COMPOUND, COMPOUND FOR USE IN THE TREATMENT OF A PATHOLOGICAL CONDITION, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR PREPARING SAID COMPOUND 审中-公开
公开(公告)号：WO2018188785A1
公开(公告)日：2018-10-18
申请号：PCT/EP2018/000176
申请日：2018-04-10
申请人： TECHNISCHE UNIVERSITÄT MÜNCHEN , DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ)
发明人： SCHWALBE, Harald , KUSTER, Bernhard , MÉDARD, Guillaume , HEINZLMEIR, Stephanie , KUDLINZKI, Denis
IPC分类号： C07D417/12 , C07D277/56 , A61K31/426 , A61P35/00
摘要： The invention concerns a compound, wherein the compound is a substance according to the following formula (I) wherein the ring A is a pyrrolidine, piperidine, morpholine, or imidazole residue or a substituted pyrrolidine, piperidine, morpholine, or imidazole residue, Q is -NH-, -NH-alkyl-, -0-, or -S- and R 7 is -H, a substituted or non-substituted pyrrolidine, morpholine, triazine, or imidazole residue, or a multiply substituted or non-substituted piperidine residue, or a substituted or non-substituted alkylpyrrolidine, alkylpiperidine, alkylmorpholine, alkyltriazine, or alkylimidazole residue, alkyl, alkylester, alkenyl, alkenylester, alkynyl, alkynylester, aminoalkyl, cyanyl, -NO 2 , methylsulfonyl residue, or a non- substituted cycloalkyi residue, or a substituted or non-substituted form of any of the following residues: cycloalkylalkyi, cycloalkenyl, cycloalkenylalkyi, bicycloalkyi, bicycloalkylalkyi, bicycloalkenyl, bicycloalkenylalkyl, or another bicyclic residue, aryl, aminoaryl, heteroaryl, heteroaminoaryl, cyclyl, aminocyclyl, heterocyclyl, heteroaminocyclyl, aralkyl, aminoaralkyl, heterocycloalkyl, or heteroaminocycloalkyl, R2 is H, -CI, -Br, -CF 3 , -CH=CH 2 or another alkenyl, -C≡CH or another alkynyl, phenyl or substituted phenyl, triazolyl or another heteroaryl, substituted triazolyl or another substituted heteroaryl, a residue of 9-BBN (9- borabicyclo[3.3.1 ]nonane), OBBD (9-oxa-10-borabicyclo[3.3.2]decane), trifluoroborate, boronic acid, or an ester of boronic acid and pinacol, methyliminodiacetic acid (MIDA), catechol, pinane diol, ethylene glycol, or propane diol or another boronic acid ester, pyrrolidine, piperidine, morpholine, or imidazole residue or a substituted pyrrolidine, piperidine, morpholine, or imidazole residue, Q is -NH-, -NH-alkyl- -0-, or -S- and R 7 is -H, a substituted or non-substituted pyrrolidine, morpholine, triazine, or imidazole residue, or a multiply substituted or non-substituted piperidine residue, or a substituted or non-substituted alkylpyrrolidine, alkylpiperidine, alkylmorpholine, alkyltriazine, or alkylimidazole residue, alkyl, alkylester, alkenyl, alkenylester, alkynyl, alkynylester, aminoalkyl, cyanyl, -NO 2, methylsulfonyl residue, or a non-substituted cycloalkyi residue, or a substituted or non-substituted form of any of the following residues: cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyi, bicycloalkyi, bicycloalkylalkyi, bicycloalkenyl, bicycloalkenylalkyi, or another bicyclic residue, aryl, aminoaryl, heteroaryl, heteroaminoaryl, cyclyl, aminocyclyl, heterocyclyl, heteroaminocyclyl, aralkyl, aminoaralkyl, heterocycloalkyl, or heteroaminocycloalkyl, R 3 is -H or -CH 3 , R 4 is -H, -CI, -Br, -CH 3 , -CH(CH 3)2 or -C(CH 3)3 , R 5 is -H, -CH 3 , -CH(CH 3)2 or -C(CH 3)3 , and R 6 is -H or -CH 3 , or a salt of said substance.

3. 发明申请

WO2017202816A1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES 审中-公开
标题翻译： 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺
公开(公告)号：WO2017202816A1
公开(公告)日：2017-11-30
申请号：PCT/EP2017/062355
申请日：2017-05-23
申请人： BAYER PHARMA AKTIENGESELLSCHAFT , DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ)
发明人： SCHMEES, Norbert , GUTCHER, Ilona , IRLBACHER, Horst , BADER, Benjamin , ZHAO, Na , PLATTEN, Michael
IPC分类号： C07D237/16 , C07D237/20 , C07D403/12 , C07D405/12 , A61P35/00 , A61K31/501
摘要： The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
摘要翻译：本发明涵盖通式（I）的3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺化合物：其中R 1，R 2，R 3，R 4，R 5 和R6如本文所定义，制备所述化合物的方法，用于制备所述化合物的中间体化合物，包含所述化合物的药物组合物和组合以及所述化合物在制备用于治疗或预防疾病，特别是癌症或具有10个失调的免疫应答或与异常AHR信号传导相关的其他障碍的病症，作为单独药剂或与其他活性成分组合。

4. 发明申请

WO2012062905A3 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS 审中-公开
公开(公告)号：WO2012062905A3
公开(公告)日：2012-05-18
申请号：PCT/EP2011/069940
申请日：2011-11-11
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) , RUPRECHTS-KARLS-UNIVERSITÄT HEIDELBERG , BOUTROS, Michael , MASKEY, Rajendra-Prasad , KOCH, Corinna , FUCHS, Florian , STEINBRINK, Sandra , GILBERT, Daniel
发明人： BOUTROS, Michael , MASKEY, Rajendra-Prasad , KOCH, Corinna , FUCHS, Florian , STEINBRINK, Sandra , GILBERT, Daniel
IPC分类号： C07D311/96 , C07D413/04 , C07D491/04 , C07D493/04 , A61K31/352 , A61K31/436 , A61K31/4741 , A61K31/519 , A61P35/00
摘要： Compounds according to the general formula (I) wherein X 1 , X 2 , X 3 and X 4 independently from each other are N or CR 8 wherein R 8 may be same or different, and wherein up to 3 of the group X 1 , X 2 , X 3 and X 4 may be N; A is a 5- or 6-membered aromatic or heteroaromtic cycle containing 1 to 3 heteroatoms selected from the group consisting of N, O and S wherein A may be substituted by 1 to 5 substituents R which may be same or different; their solvates, hydrates, and pharmaceutically acceptable salts for the treatment of a disorder or disease associated with an aberrant activation of Wnt signalling in a mammal selected from a cell proliferative disorder, rheumatoid arthritis, increased bone density, aging or age-related disorders and/or diseases or Dupuytren disease (superficial fibromatosis).

5. 发明申请

WO2012062901A2 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS 审中-公开
标题翻译：铬衍生物及其作为WNT路径拮抗剂的ANALOGA
公开(公告)号：WO2012062901A2
公开(公告)日：2012-05-18
申请号：PCT/EP2011/069927
申请日：2011-11-11
申请人： Deutsches Krebsforschungszentrum (DKFZ) , Ruprechts-Karls-Universität Heidelberg , BOUTROS, Michael , MASKEY, Rajendra-Prasad , KOCH, Corinna , FUCHS, Florian , STEINBRINK, Sandra , GILBERT, Daniel
发明人： BOUTROS, Michael , MASKEY, Rajendra-Prasad , KOCH, Corinna , FUCHS, Florian , STEINBRINK, Sandra , GILBERT, Daniel
IPC分类号： C07D311/58 , C07D491/04 , C07D493/04 , A61K31/353 , A61K31/357 , A61P35/00
CPC分类号： C07D311/92 , C07D311/04 , C07D311/96 , C07D413/04 , C07D491/04 , C07D491/052 , C07D493/04
摘要： Compounds of formula (IIc); wherein X 3 and X 4 independently from each other are N or CR 8 wherein R 8 may be same or different; Y 1 , Y 2 , Y 3 and Y 4 independently from each other are N or CR 9 wherein R 9 may be same or different and wherein up to 3 of the group Y 1 , Y 2 , Y 3 and Y 4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.
摘要翻译：式（IIc）化合物; 其中X3和X4彼此独立地是N或CR8，其中R8可以相同或不同; Y1，Y2，Y3和Y4彼此独立地是N或CR9，其中R9可以相同或不同，并且其中Y1，Y2，Y3和Y4中的至多3个可以是N; 其溶剂合物，水合物和药学上可接受的盐，其用于调节Wnt信号传导途径活性及其作为药物的用途的用途，优选用于治疗癌症。

6. 发明申请

WO2009068615A1 EX VIVO METHOD FOR PRODUCING A PREPARATION CONTAINING CD4+ T CELLS SPECIFIC FOR EBV STRUCTURAL ANTIGENS 审中-公开
标题翻译：用于生产含有EBV结构抗原特异性CD4 + T细胞的制备物的生物方法
公开(公告)号：WO2009068615A1
公开(公告)日：2009-06-04
申请号：PCT/EP2008/066347
申请日：2008-11-27
申请人： HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) , DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) , ADHIKARY, Dinesh , BEHRENDS, Uta , MAUTNER, Josef , DELECLUSE, Henri-Jacques , FEEDERLE, Regine
发明人： ADHIKARY, Dinesh , BEHRENDS, Uta , MAUTNER, Josef , DELECLUSE, Henri-Jacques , FEEDERLE, Regine
IPC分类号： C12N5/06 , A61K35/12 , A61P37/04
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/5158 , A61K2039/5258 , C12N5/0636 , C12N2502/11 , C12N2710/16234
摘要： The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.
摘要翻译：本发明公开了一种用于制备含有EBV结构抗原特异性CD4 + T细胞的制剂的离体方法，用于预防和治疗T细胞活性降低的患者，以预防或治疗EBV感染的B细胞的生长。

7. 发明申请

WO2003057203A3 BIOMATERIALS BASED ON HYALURONIC ACID FOR THE ANTI-ANGIOGENIC THERAPY IN THE TREATMENT OF TUMOURS 审中-公开
公开(公告)号：WO2003057203A3
公开(公告)日：2003-07-17
申请号：PCT/EP2003/000078
申请日：2003-01-07
申请人： FIDIA FARMACEUTICI S.P.A. , DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) , FUSENIG, Norbert, E. , STARK, Hans-Jürgen , WILLHAUCK, Michael , PAVESIO, Alessandra
发明人： FUSENIG, Norbert, E. , STARK, Hans-Jürgen , WILLHAUCK, Michael , PAVESIO, Alessandra
IPC分类号： A61L27/00
摘要： The use in the medical-surgical field of biomaterials based on hyaluronic acid derivatives, optionally in association with natural, synthetic or semisynthetic biopolymers, for suppressing the angiogenic process associated with tumour proliferation (in primary and secondary tumours) is disclosed.

8. 发明申请

WO2019023812A1 MALARIA VACCINE COMPOSITION AND METHOD 审中-公开
公开(公告)号：WO2019023812A1
公开(公告)日：2019-02-07
申请号：PCT/CA2018/050955
申请日：2018-08-03
申请人： THE HOSPITAL FOR SICK CHILDREN , DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ)
发明人： JULIEN, Jean-Philippe , SCALLY, Stephen , BOSCH, Alexandre , IMKELLER, Katharina , WARDEMANN, Hedda , MURUGAN, Rajagopa
IPC分类号： C07K19/00 , A61K39/015 , A61K39/385 , A61P33/06 , A61P37/04 , C07K14/445 , C07K16/00 , C07K16/20 , C12N15/62
CPC分类号： A61P33/06 , A61K39/015 , A61K39/385 , A61K2039/6056 , A61P37/04 , C07K14/445 , C07K16/00 , C07K16/205 , C07K19/00 , C07K2317/55 , C07K2317/76 , C07K2317/92 , C07K2319/01 , C12N15/62
摘要： A fusion protein comprises: an antigen comprising at least a first and a second antibody-binding epitope; and an antibody or fragment thereof specific for at least the first antigen epitope; wherein binding of the antibody or fragment thereof to the first antigen epitope presents the second antigen epitope for binding to an antigen-binding moiety.

9. 发明申请

WO2017085191A1 NEW TUMOR MARKER FOR THE RHABDOMYOSARCOMA 审中-公开
标题翻译：新的肿瘤标志物为RHABDOMYOSARCOMA
公开(公告)号：WO2017085191A1
公开(公告)日：2017-05-26
申请号：PCT/EP2016/078015
申请日：2016-11-17
申请人： EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET , DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ)
发明人： GESCHE, Jens , ARMEANU-EBINGER, Sorin , SEITZ, Guido , SUROWY, Harald
IPC分类号： C07K14/705 , C07K16/28
CPC分类号： C07K14/705 , C12Q1/6886 , C12Q2600/156 , G01N33/574
摘要： The present invention relates to a nucleic acid molecule which encodes a splice variant of the human P2RX7 receptor, and nucleic acid molecules derived therefrom, a recombinant vector containing said nucleic acid molecules, a host containing said recombinant vector, a polypeptide encoded by said nucleic acid molecules, a host cell expressing said polypeptide, a binding molecule binding to said polypeptide, a pharmaceutical composition comprising said binding molecule, a method for the production of the isolated polypeptide, and other methods and uses in connection therewith.
摘要翻译：本发明涉及编码人P2RX7受体的剪接变体的核酸分子和由其衍生的核酸分子，含有所述核酸分子的重组载体，含有所述重组载体的宿主，由所述核酸分子编码的多肽，表达所述多肽的宿主细胞，与所述多肽结合的结合分子，包含所述结合分子的药物组合物，用于产生分离的多肽的方法，以及其它连接方法和用途与其

10. 发明申请

WO2012143481A2 PROSTATE CANCER MARKERS 审中-公开
标题翻译：前列腺癌标志物
公开(公告)号：WO2012143481A2
公开(公告)日：2012-10-26
申请号：PCT/EP2012/057225
申请日：2012-04-19
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. , DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) , SCHWEIGER, Michal , LEHRACH, Hans , BÖRNÖ, Stefan , SCHLOMM, Thorsten , SÜLTMANN, Holger , SAUTER, Guido
发明人： SCHWEIGER, Michal , LEHRACH, Hans , BÖRNÖ, Stefan , SCHLOMM, Thorsten , SÜLTMANN, Holger , SAUTER, Guido
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/154
摘要： The invention relates to the identification and selection of novel genomic regions (biomarker) and the identification and selection of novel genomic region combinations which are hypermethylated in subjects with prostate cancer compared to subjects without prostate cancer. Nucleic acids which selectively hybridize to the genomic regions and products thereof are also encompassed within the scope of the invention as are compositions and kits containing said nucleic acids and nucleic acids for use in diagnosing prostate cancer. Further encompassed by the invention is the use of nucleic acids which selectively hybridize to one of the genomic regions or products thereof to monitor disease regression in a patient and the efficacy of therapeutic regimens.
摘要翻译：本发明涉及鉴定和选择新基因组区域（生物标志物）以及与前列腺癌患者相比，在前列腺癌患者中高甲基化的新基因组区域组合的鉴定和选择。与基因组区域及其产物选择性杂交的核酸也包括在本发明的范围内，以及含有用于诊断前列腺癌的所述核酸和核酸的组合物和试剂盒。本发明进一步包括使用选择性地与其中一个基因组区域或其产物杂交以监测患者的疾病回归和治疗方案的功效的核酸。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式